Medpage Today on MSN
Wet AMD: Tips on Navigating Anti-VEGF Drug Options
According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...
On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd.
After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...
Khanani MD, MA, FASRS, Sierra Eye Associates in Reno, NV, for an overview of the preclinical pharmacology and toxicology studies that underpin the program’s novel platform, the IND‑enabling package ...
Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025Phase 1b/2 Multiple Ascending Dose ...
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback